Zentalis Pharmaceuticals (ZNTL) director awarded 57,100 RSUs
Rhea-AI Filing Summary
Myers Scott Dunseth reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Scott Dunseth Myers received a grant of 57,100 restricted stock units (RSUs). The award was made at no cash cost and increases his direct holdings to 395,895 shares of common stock. The RSUs vest on the earlier of June 16, 2027 or the next annual stockholder meeting, subject to his continued board service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Myers Scott Dunseth
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 57,100 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 395,895 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
RSU grant size: 57,100 units
Grant price: $0.00 per share
Holdings after transaction: 395,895 shares
+1 more
4 metrics
RSU grant size
57,100 units
Restricted stock units granted to director on June 16, 2026
Grant price
$0.00 per share
RSUs granted at no cash cost to the director
Holdings after transaction
395,895 shares
Total direct Zentalis common stock holdings after RSU grant
RSU vesting date
June 16, 2027
Vests on earlier of this date or next annual stockholder meeting
Key Terms
restricted stock units, Non-Employee Director Compensation Program, contingent right, vesting
4 terms
restricted stock units financial
"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Non-Employee Director Compensation Program financial
"restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program"
contingent right financial
"each of which represents a contingent right to receive one share of common stock"
vesting financial
"which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Zentalis (ZNTL) director Scott Dunseth Myers report on this Form 4?
Scott Dunseth Myers reported receiving 57,100 restricted stock units in Zentalis Pharmaceuticals common stock. These RSUs were granted as director compensation and increase his direct holdings to 395,895 shares after the transaction, according to the Form 4 details and accompanying footnote.
What are the vesting terms of Scott Dunseth Myers’ RSU grant at Zentalis (ZNTL)?
The 57,100 restricted stock units vest on the earlier of June 16, 2027 or the next annual meeting of Zentalis stockholders. Vesting is conditioned on Myers’ continued service on the company’s Board of Directors through the applicable vesting date, per the footnote.
Was Scott Dunseth Myers’ Zentalis (ZNTL) RSU grant an open-market purchase?
No, the Form 4 shows the transaction code "A," indicating a grant or award, not an open-market purchase. The RSUs were granted at a price of $0.00 per share as part of the company’s Non-Employee Director Compensation Program, rather than bought in the market.
What does each Zentalis (ZNTL) RSU granted to Scott Dunseth Myers represent?
Each restricted stock unit represents a contingent right to receive one share of Zentalis common stock. The units convert into shares only upon vesting, which occurs on the earlier of June 16, 2027 or the next annual stockholder meeting, assuming continued board service.